Objective: We aimed to investigate significance of smoking regarding pathologic and biochemical outcomes following radical prostatectomy (RP).
Materials and methods: We reviewed data of 1,165 patients who underwent RP without any neoadjuvant or adjuvant therapy at our institution. Patients were categorized into two groups for our analysis: smoking (current smoker at admission for surgery) and nonsmoking (never smoked or former smokers) group. Association of smoking status with adverse pathologic features and biochemical recurrence-free survival were analyzed according to patients' body mass index (BMI) as well as in total patients.
Results: In multivariate analyses, smoking was not found to be significantly associated with various adverse pathologic features and biochemical recurrence-free survival among total patients (all P > 0.05). However, when only the patients with BMI ≥ 25 kg/m(2) were analyzed, smoking at RP was observed to be an independent preoperative predictor of high (≥ 8) pathologic Gleason score (P = 0.025) and biochemical recurrence-free survival (P = 0.016) in multivariate analyses.
Conclusions: Although smoking was not observed to be significantly associated with worse pathologic and biochemical outcome among overall patients who underwent RP, smoking was found to be a significant preoperative predictor of more aggressive disease and worse biochemical outcome among those with relatively higher BMI.